ClinicalTrials.gg
RecruitingNCT07148128Updated Jan 29, 2026

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

A Phase 1/2 interventional study of WEF-001 in Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer and Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, sponsored by Auricula Biosciences Inc.. Recruiting at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-29.

Primary conditionnone(registry's first term: Pancreatic Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Pancreatic Neoplasms, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by Auricula Biosciences Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.

02

Conditions studied

  • Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma
  • Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer
  • Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer
  • Advanced Solid Tumors
  • Advanced or Metastatic KRAS-mutant Tumor

Keywords

  • Antineoplastic Agents
  • Advanced Solid Tumors
  • Pancreatic Cancer
  • Colorectal Cancer
  • KRAS Mutation-Related Tumors
  • Lung Cancer
  • Carcinoma, Non-Small Cell Lung Cancer
  • Non-Small Cell Lung Cancer
03

In context

Lead sponsor

This is the only study on the registry with Auricula Biosciences Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced KRAS-mutant solid tumor: pancreatic ductal adenocarcinoma, colorectal cancer, non small cell lung cancer, platinum-resistant serous ovarian cancer, cholangiocarcinoma or urothelial bladder cancer
  • Progressive disease following at least one line of standard of care therapy
  • as defined by v1.1
  • ≤ 1

Exclusion criteria

Exclusion Criteria:

  • Active systemic infection requiring anti-infective therapy within 28 days prior to first dose of IMP
  • Active cardiovascular disease
  • Having a second active primary , requiring systemic administration of any cancer-related therapy
  • Liver dysfunction
  • Untreated and/or unstable neurological dysfunction
  • Inflammatory bowel disease
  • Active and untreated hyperthyroidism
  • Lupus erythematosus within past 5 years
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Dose selection

    Phase 1: WEF-001 will be administered to participating patients at 1 selected dose out of 7 possible doses. Phase 2: WEF-001 will be administered to participating patients at 1 selected dose out of 2 possible doses.

    Drug: WEF-001

Interventions

  • DrugWEF-001

    Starting dose of 0.3 mg/m2 q4wks IV, dose escalation

    Also known as: MMAE-Drug Conjugate

06

What researchers measure

Primary outcomes

  1. Phase 1: To characterize the safety and tolerability profiles of WEF-001 administered as monotherapy.

    Type, incidence and severity of TEAEs, SAEs and abnormal laboratory values per CTCAE v5.0. Frequency of dose interruptions, reductions, and discontinuations. Proportion of participants with DLTs at each dose level.

    Time frame: Through study completion, an average of 1 year.

  2. Phase 2: To evaluate the antitumour activity following WEF-001 administration as monotherapy.

    Objective Response Rate according to Response Evaluation Criteria in Solid Tumor (RECIST) v 1.1

    Time frame: Trough study completion, an average of 2 years.

07

Study locations

4 of 4 sites recruiting
  • NEXT Oncology Dallas
    Dallas, Texas 75230, United States
    Recruiting
  • Next Oncology, San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
  • Princess Margareth Cancer Center
    Toronto, Ontario, Canada
    Recruiting
    • Anna Spreafico, MD, PhD · Principal investigator
  • Oxford University Hospital
    Headington, Oxford 0X3 9DU, United Kingdom
    Recruiting
    • Mark Middleton, MD, FRCP (UK), PhD · Principal investigator
    • Magdalena Kielak, MD · Sub investigator
    • Simon Lord, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jan 2028, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2025
First posted
Aug 29, 2025
StartActual
Jul 28, 2025
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07148128
Lead sponsor
Auricula Biosciences Inc.
Collaborators
Simbec-Orion Group
Responsible party
Sponsor
First posted
Aug 29, 2025
Start date
Jul 28, 2025
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jan 29, 2026

Study contacts

Michele Finn, MSc
Contact
inquiries@auriculabiosciences.com
1-438-884-9551

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion